Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.

摘要: The cost-effectiveness of epoetin alfa therapy for anemia in 20 patients with end-stage renal disease was retrospectively studied. Ten on continuous ambulatory peritoneal dialysis (CAPD) were given subcutaneous as part a multicenter, protocol-controlled study the efficacy alfa. in-center hemodialysis intravenous their routine clinical care. Change hematocrit used measure effectiveness Medication, laboratory, and transfusion costs monitored six months preceding initiation first treatment. cost increased all by an average $2722 +/- 1118; decreased, whereas medication laboratory increased. Laboratory significantly greater CAPD than during therapy; no significant differences or noted between groups. mean increase 7.4 volume percent. Following initial change hematocrit, further therapeutic response did not appear to be determined increasing expenditures. Epoetin shown effective treating disease, but it associated higher therapy.